Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, reported its first-quarter 2026 operational highlights and financial results, showcasing a 47% year-over-year reduction in research and development spending. The company advanced multiple clinical programs through key regulatory milestones, including a successful FDA Type C meeting outcome for the Phase 2 HARMONIC trial of LP-300 and IND clearance for Starlight Therapeutics' first pediatric CNS cancer program.
The company also launched withZeta.ai, its multi-agentic AI drug development platform, and outlined plans to separate its AI assets into an independent entity. Recent financing of up to $9.25 million extends Lantern's operating runway into the first quarter of 2027.
Lantern Pharma is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR(R) platform to transform the development of cancer therapies. Its clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary.
withZeta.ai, Lantern's multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the company. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.
The company's focus on cost reduction while advancing its pipeline underscores its commitment to efficient drug development. The 47% decrease in R&D spending, coupled with progress in clinical trials, highlights the potential of AI to streamline oncology research and reduce costs. The FDA's positive response to the HARMONIC trial and the IND clearance for the pediatric CNS program mark significant steps forward for Lantern's pipeline.
For more information on Lantern Pharma, visit the company's newsroom at https://ibn.fm/LTRN.
